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Recent success in checkpoint blockade therapies has 
provided a model example of targeted immunotherapies 
with strong and durable efficacy but only in a restricted 
responsive patient population [1, 2]. This suggests 
that checkpoint-mediated regulation is the basis of 
immunosuppression for those tumors, whereas the immune 
system is inactivated via other mechanisms, or their 
combinations, in other patients. A better understanding 
of these different routes to immunosuppression will 
enable us to effectively target immunosuppression in a 
personalized manner. This is also true for brain tumors, 
such as glioblastoma (GBM), which is an aggressive 
diffuse glioma type with an extremely poor prognosis 
[3]. Glioblastoma microenvironment typically includes 
high macrophage/microglia counts and few T cells [4]. 
While low in numbers, T cells are present in glioblastoma 
microenvironment, and T cell infiltration positively 
correlates with clinical outcome in these patients [4]. In 
principle, tumor-associated microglia and macrophages 
(TAMs) can attack malignant cells and have the capacity 
to present antigens to T cells upon activation, but they 
typically instead contribute to the immunosuppression 
and may even promote proliferation and progression 
of malignant cells [4, 5]. Consistently, they have been 
associated with poor patient prognosis. 
The Cancer Genome Atlas (TCGA) recently 
analyzed cancer immune landscape across 33 tumor types 
and distributed tumors into six immune subtypes [6]. These 
subtypes are associated with differences in macrophages 
and lymphocytes, intratumoral heterogeneity, genomic 
landscape, cell proliferation, and prognosis [6]. This 
demonstrates that the immune system - tumor interaction 
can be categorized into relevant subtypes, which are not 
limited to a single tumor type. This analysis provides an 
overall framework for cancer immunology. Prevalent 
immune subtypes were clearly different in GBM and 
low-grade diffuse gliomas than in other tumors types 
[6], highlighting the immunological uniqueness of these 
tumors and the surrounding nervous tissue. Our recently 
published characterization of TCGA GBM cohort provides 
a complementary view to the immune landscape in GBM 
[7]. We used a data-driven approach to define gene clusters 
and sample groups which are relevant for glioblastoma 
immunology. These features were also associated with 
deconvolution-based estimates of relative immune 
cell type proportions as well as the clinical and genetic 
characteristics of the tumors. As we analyzed the data from 
a multitude of perspectives, we were able to investigate 
both the immune cell proportions and the nature of the 
immune response present in the tumor microenvironment, 
thus extending our understanding of immunosuppression 
in GBM.
As a result, we observed high variation in the 
immune response -related gene signatures and estimated 
immune cell proportions, suggesting patient-to-patient 
variation in the modes of immune suppression. Sample 
clustering based on the discovered immune gene 
signatures identified three major tumor microenvironment 
subgroups: negative, humoral, and cellular-like (Figure 1). 
They can be considered to represent three general modes 
of immunosuppression in GBM, especially in respect to 
adaptive immune response. 
Estimated immune cell proportions in GBM 
samples support our subgrouping, e.g., high B and CD4+ 
T cell proportions and low CD8+ T cell proportions were 
mainly observed in the humoral subgroup. The negative 
subgroup was characterized by the low activity of most 
immune response-related gene clusters and low immune 
cell recruitment when compared to other subgroups. All 
the IDH-mutated tumors were in this group, consistently 
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Figure 1: The possible mechanism of 
immunosuppression in samples with IDH1 mutation. 
The expression of MHC I -type HLA genes is lowest in the 
negative subgroup and their DNA methylation levels are high 
in samples with an IDH1 mutation when compared to other 
samples. This suggests epigenetic silencing of HLA expression 
in IDH1 mutant tumors which potentially decreases MHC-I 
mediated antigen presentation in IDH1 mutant cells.
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with [6, 8]. Cellular-like subgroup contained samples with 
high activity of gene clusters ‘negative regulation of T cell 
activation, PD-L1’ and ‘gamma delta T cells’. However, 
CD8+ T cell recruitment to the tumor microenvironment, 
which should take place for proper anti-tumor immune 
response, was not significantly increased. 
The obtained subgroups, cluster activities, and 
immune cell proportions showed associations with patient 
survival, GBM subtypes and typical genetic alterations 
in GBM (such as IDH mutation, inactivating NF1 
alteration, and CDK4-MARCH9 locus amplification) [7]. 
NF1 inactivation was associated with activated innate 
immunity (increased granulocyte and TAM recruitment 
as well as TAM response) but not with our immune 
subgrouping, which is partly dependent on the adaptive 
immune response, as well. Interestingly, most of the strong 
genetic associations distinguished negative subgroup from 
the others but did not make a clear distinction between 
humoral and cellular subgroups. Although the small size 
of the humoral subgroup can contribute to the results, 
this also suggests that the studied genetic features are 
influencing more the level of adaptive immune response 
than the type of response. In general, MHC I -mediated 
antigen presentation, which is needed for CD8+ T cell 
activation, appears to be decreased in the negative group 
(Figure 1). For example, different MHC I -type HLA 
genes have the lowest expression in the negative subgroup 
and the highest in the cellular-like group [7]. The lowest 
expression of these HLA genes is in the samples with 
either IDH1 mutation or amplification of CDK4-MARCH9 
locus. Furthermore, HLA genes are significantly more 
methylated in samples with IDH1 mutation than in 
other tumors, suggesting epigenetic silencing of HLA 
expression in IDH1 mutant tumors (Figure 1). This also 
seems to be the case, as HLA protein expression was 
lowest in an IDH-mutant cell line among diffuse glioma 
cell lines and methyltransferase inhibition was able to 
release this suppression and increase HLA expression in 
our experiments [7]. This also has clinical implications, 
as improved antigen presentation might be a potential 
intervention option for cases in the negative subgroup. In 
the future, revealed different modes of immunosuppression 
in GBM together with associated molecular features can 
guide patient stratification and therapeutic interventions. 
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